Compare CMPX & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMPX | GBLI |
|---|---|---|
| Founded | 2014 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.8M | 398.7M |
| IPO Year | 2020 | 2010 |
| Metric | CMPX | GBLI |
|---|---|---|
| Price | $2.52 | $29.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $14.57 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 3.1K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | N/A | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | $934.41 | $9.68 |
| P/E Ratio | ★ N/A | $27.62 |
| Revenue Growth | N/A | ★ 2.02 |
| 52 Week Low | $1.61 | $24.28 |
| 52 Week High | $6.88 | $30.52 |
| Indicator | CMPX | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 60.99 |
| Support Level | $1.68 | $27.45 |
| Resistance Level | $5.70 | $29.16 |
| Average True Range (ATR) | 0.14 | 0.85 |
| MACD | 0.03 | 0.07 |
| Stochastic Oscillator | 83.86 | 100.00 |
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.